Examination of the immunity and the blood clotting in patients with advancer non-small cell lung cancer treated with bevacizumab.Accompaniment research of TORG1321 study (UMIN000010681) - Examination of the immunity and the blood clotting in patients with advancer non-small cell lung cancer treated with bevacizumab(TORG1321-S).

Thoracic Oncology Research Group0 个研究点目标入组 8 人开始时间: 2018年1月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•First step(induction) 1)Symptomatic brain metastasis 2)Current history of hemoptysis 3)With pulmonary cavity lesions 4)History of radical thoracic radiotherapy 5)Active infections diseases 6)Fever over 38 degrees centigrade 7)Serious complications 8)Massive pleural and cardiac effusion and ascites that need to be immediately treated 9)Active concomitant cancers 10)Severe drug allergy 11)Uncontrollable ulcer indigestive tract 12)Perforation of the digestive tract or history within the past one year 13)Receiving anticoagulant drug (325mg and less aspirin is possible) 14) Pregnancy, breastfeeding or suspected of being pregnant 15)Those judged to be not suitable by the attending physician Second step (maintenance) 1)Symptomatic brain metastasis 2)Accompanied by serious complication in induction therapy 3) Severe drug allergy for PEM or BEM or severe adverse effect in induction therapy

发起方

Thoracic Oncology Research Group